Genzyme

GenzymeGenzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

www.genzyme.com

Genzyme RSS Channel

Display # 
Title Published Date
Sanofi Genzyme announces recipients of Patient Advocacy Leadership (PAL) awards 06 January 2016
Genzyme introduces "vs.MS," a global initiative aimed at uncovering the often unspoken challenges of MS to drive better informed care 05 October 2015
Genzyme recognizes World MS Day 30 May 2012
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients 22 January 2012
Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration 16 November 2011
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab in Multiple Sclerosis 12 July 2011
Genzyme Celebrates 20th Anniversary of Gaucher Disease Registry with Launch of New Web Platform 17 June 2011
Genzyme Revenues Grow in First-Quarter 2011 29 April 2011
Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease 15 April 2011
Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares 07 March 2011
Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program 28 February 2011
Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year 16 February 2011
Genzyme Will Allow sanofi-aventis to Conduct Due Diligence 31 January 2011
Genzyme to Build Additional Plant to Support Growth of Myozyme® and Lumizyme® 20 January 2011
Genzyme Financial Recovery Continues in Fourth Quarter 11 January 2011
Genzyme Statement on Discussions With Sanofi-Aventis 10 January 2011
Genzyme Details Market Potential of Alemtuzumab for MS 20 December 2010
Genzyme Reiterates Board's Position on sanofi-aventis Tender Offer 13 December 2010
Genzyme Completes Sale of Genetic Testing Business to LabCorp 01 December 2010
Genzyme Announces Agreement to Sell Diagnostics Business 18 November 2010

Most Popular Now

One family's history of the rare co…

In recognition of International Fabry Awareness month, Shire has released the trailer for Our Fabry Family Tree, a short film series featuring a family who were unknowing...

Read more

What's the secret to living a full …

If you have ever asked yourself, "What makes me feel most fulfilled?" you are not alone. Nearly 2 million people recently answered that question in a new survey by Abbott...

Read more

Bristol-Myers Squibb reports first …

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2016, which were highlighted by strong sales for Opdivo, Eliquis and our hepatitis...

Read more

Researchers discover potential trea…

Researchers at the Icahn School of Medicine at Mount Sinai say that tiny doses of a cancer drug may stop the raging, uncontrollable immune response to infection that lead...

Read more

2016 Otto Bayer Award goes to Profe…

The award-winner of the 2016 Otto Bayer Award has been named: the Board of Trustees of the Bayer Science & Education Foundation and the Scientific Committee for this awar...

Read more

Bayer off to a successful start in …

The Bayer Group got off to a successful start in the new fiscal year. "All segments posted gains in their operating performance," said CEO Dr. Marijn Dekkers when he pres...

Read more

Ready. Raise. Rise. Campaign

The Ready. Raise. Rise. campaign encourages everyone to raise and share a flag to salute those who have been touched by cancer, especially patients and caregivers, and le...

Read more

Pfizer reports first-quarter 2016 r…

Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2016 and updated certain components of its 2016 financial guidance. Reported revenues totaled $13.0 b...

Read more

Research points to a new treatment …

Researchers have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis, pointing to a potential new treatment using drugs previously ...

Read more

'Mediterranean' diet linked to lowe…

A "Mediterranean" diet, high in fruit, vegetables, fish and unrefined foods, is linked to a lower risk of heart attack and stroke in people who already have heart disease...

Read more

Merck brings international start-up…

Merck, a leading science and technology company, has announced the participants for its Accelerator Programs in Darmstadt and Nairobi. Almost 200 highly competitive appli...

Read more

Why are women less likely to be pre…

Statins are equally effective at decreasing risk of coronary events in men and women, and yet women are less likely to be prescribed these cholesterol-lowering drugs than...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]